Preparing your ERP for life sciences commercialization

Life sciences companies spend years preparing a product for FDA approval. But many spend far less time preparing to operate a commercial business.

The day a therapy reaches the market may signal the end of clinical development, but it also marks the beginning of an entirely new operating model. Suddenly, success depends not only on scientific innovation but also on the ability to manage inventory, coordinate manufacturing partners, maintain regulatory controls, fulfill customer demand, and understand product profitability.

As manufacturing partners get ready for launch and commercial teams finalize pricing, reimbursement, and go-to-market strategies, operational questions quickly emerge:

• Are our systems ready to support commercial manufacturing?
• Can we trace every lot from raw material to finished product?
• Do we have visibility into product costs and supply chain performance?
• How will quality approvals be managed?

The systems and processes that supported a research-focused business are fundamentally different from those required to run a commercial business. That disconnect creates a commercialization readiness gap, something many companies discover too late.

Compounding this challenge is the fact that emerging life sciences organizations rarely bring all commercial operations in-house, instead relying on outsourcing to manufacture, package, and distribute products. While this can accelerate growth and improve flexibility, it also increases the need for visibility, coordination, and control across an extended supply chain.

The organizations that experience the smoothest commercial launches recognize that operational readiness doesn’t begin at FDA approval. It begins months (or sometimes years) earlier by ensuring their ERP, business processes, and operating model are ready to support the realities of the commercialization life.

Commercialization is more than a product launch

Many organizations view the day a product reaches the market as the finish line. In reality, commercialization is a transition from one operating model to another.

During the clinical stage, organizations typically focus on activities such as:

• Research and development
• Clinical trial management
• Fundraising and investor reporting
• Indirect procurement
• Limited inventory management

Once commercialization begins, entirely new operational requirements emerge, including:

• Commercial inventory management
• Demand forecasting
• Manufacturing oversight
• Direct procurement
• Distribution and fulfillment
• Regulatory controls and audit readiness
• Cost accounting and profitability analysis

Consider a biotech company preparing to launch its first therapy.

During clinical development, it may only need enough inventory management to support clinical trials. Once approved, however, it must coordinate manufacturing schedules with a CDMO, track inventory across multiple warehouses, monitor product releases, fulfill customer demand, and understand the true cost of every product shipped.

Enterprise resource planning software configured to support clinical-stage operations isn’t typically designed to support these realities.

Why so many companies wait too long

It’s easy to understand why commercialization planning gets delayed.

When a business is focused on clinical milestones, commercialization can feel far away, leading to assumptions like:

• “We’ll deal with that after approval.”
• “Our manufacturing is outsourced, so we don’t need to worry about it yet.”
• “Our current processes should be able to scale.”

Unfortunately, those assumptions often lead to businesses trying to solve multiple operational challenges simultaneously.

As launch approaches, teams suddenly find themselves needing to implement inventory controls, define quality processes, establish validation strategies, integrate manufacturing partners, improve supply chain visibility, and build cost accounting capabilities under aggressive timelines, introducing unnecessary risk.

Life sciences businesses that wait too long to prepare ERP operations for commercialization may face:

• Shortened implementation timelines
• Increased compliance risk
• Manual workarounds
• Higher implementation costs
• Operational bottlenecks during product launch

The earlier organizations evaluate their future operating model, the more flexibility they have to implement technology strategically instead of reactively.

4 decisions that shape commercialization readiness

While every life sciences organization follows a different path to commercialization, several foundational decisions influence nearly every ERP strategy.

1. When should you transition to a commercial ERP environment?

One of the first questions businesses ask is whether they should implement commercial capabilities before launch, at FDA approval, or after commercialization begins. In reality, the right timing depends on:

• Product development timelines
• Organizational maturity
• Funding availability
• Supply chain complexity

Rather than tying ERP planning to a single regulatory milestone, organizations should align implementation with operational readiness.

For example, a company with a complex outsourced manufacturing network may benefit from implementing inventory and manufacturing functionality before launch to allow sufficient time for testing and process refinement. Another organization with a simpler operating model may choose a different timeline.

The goal isn’t simply to implement the technology as early as possible. The real aim should be to ensure the business is operationally ready when commercialization begins.

2. What will your manufacturing model look like?

Some organizations rely almost entirely on outsourced partners, including CMOs, CDMOs, and 3PLs. Others manufacture internally, requiring production scheduling, warehouse management, and shop floor operations. Many operate somewhere in between with a hybrid model. Each approach introduces different technology requirements.

An outsourced model places greater emphasis on partner integration, inventory visibility, and coordination across external organizations. An internal manufacturing model requires deeper production management, quality operations, and warehouse capabilities. Hybrid environments demand both.

Defining this operating model early helps organizations design supporting business processes and technology that can scale as commercialization approaches.

3. What level of validation will be required?

When it comes to ERP validation, the answer is rarely a simple yes or no. Requirements depend on how the ERP supports regulated business processes and the associated level of risk.

Rather than assuming every function requires validation, or that none does, organizations should perform a risk-based assessment that considers:

• Regulatory risk
• Business processes
• Quality impact
• Data integrity requirements

Taking this approach helps organizations determine what requires validation, when validation should occur, and how to prioritize implementation without creating unnecessary complexity.

4. Do your partners support your commercial timeline?

Successful commercialization often depends on coordinated expertise across technology implementation, regulatory compliance, quality management, supply chain strategy, validation, and ongoing operational support.

Whether implementing ERP capabilities, validating systems, integrating supply chain partners, or refining operational processes, organizations need experienced partners that understand both technology and life sciences operations.

What commercial readiness looks like inside the ERP

Because commercialization introduces varying levels of operational complexity, a commercially ready ERP should provide visibility and control across all critical business processes.

Inventory status controls

Organizations need the ability to manage inventory through statuses such as:

• Quarantine
• Released
• On hold

These controls help ensure that only approved materials are available for manufacturing, fulfillment, or distribution, as not every inventory item should immediately move through the supply chain.

Lot genealogy and end-to-end traceability

Traceability becomes increasingly important as organizations move into commercial production.

A modern ERP system like NetSuite should allow organizations to track products throughout the supply chain, including:

• Raw materials
• Suppliers
• Manufacturing batches
• Finished goods

This visibility helps organizations quickly identify affected materials during investigations, recalls, or audits while improving overall operational confidence.

Electronic signatures and audit trails

Commercial organizations also require stronger governance around approvals.

Electronic signatures, approval workflows, and comprehensive audit trails support regulatory requirements while providing a complete history of key business activities. Instead of relying on spreadsheets or disconnected systems, organizations can maintain a single source of truth for approvals and operational records.

Automated cost visibility

Commercial success depends on understanding product profitability. This means an ERP should be capable of automatically capturing costs across the manufacturing process, including:

• Raw materials
• Manufacturing activities
• External processing
• Packaging
• Testing

Rather than manually compiling data from multiple sources, finance teams gain more accurate product costing while reducing administrative effort.

Commercialization looks different than it did a decade ago

Historically, many organizations assumed commercialization required migrating to a large, tier-one ERP platform, but today’s operating models tell a different story.

Many emerging life sciences companies outsource manufacturing, packaging, warehousing, and distribution to specialized partners. Instead of managing every operational process internally, they manage an extended network of providers.

As a result, organizations are increasingly asking, “Can our ERP support the complexity of our business?” versus “Do we need a bigger ERP?” In other words, success often depends less on the size of the ERP platform and more on whether it provides visibility, integration, regulatory controls, and scalability across their unique operating model.

When should commercialization planning begin?

As organizations approach the end of Phase II clinical trials, commercialization planning often becomes a priority. While the exact timing depends on the product, manufacturing strategy, funding, and commercialization roadmap, this stage often marks the point when organizations have enough confidence in the product’s path forward to begin planning how the business will operate commercially.

Commercialization planning encompasses far more than ERP selection. It includes evaluating future business processes, defining manufacturing and supply chain strategies, assessing validation requirements, and ensuring the right operational, quality, and commercial teams are in place before launch. Organizations that begin these conversations early are better positioned to avoid rushed decisions, prepare their teams, and support a smoother transition into commercial operations.

Is your organization as ready as your product?

Launching a product is a significant achievement, but it isn’t the end of the journey. FDA approval may mark the beginning of commercialization, but operational readiness starts long before that milestone.

Once a product reaches the market, life sciences organizations often face an entirely new set of challenges, including:

• Expanding product portfolios
• Entering new markets
• Managing international subsidiaries
• Supporting intercompany transactions
• Improving demand planning
• Strengthening procurement processes
• Leveraging automation and AI
• Enhancing reporting and analytics

The systems established before launch become the operational foundation that supports everything that follows. An ERP environment built solely for clinical-stage operations can quickly become a bottleneck as commercial complexity grows.

Preparing for commercialization isn’t simply about implementing software. It’s about building the processes, controls, visibility, and flexibility needed to support a scalable commercial organization from day one. Companies that begin planning early can avoid rushed implementations, reduce operational risk, and create a stronger foundation for long-term growth.

If your organization is preparing for commercialization, now is the time to evaluate whether your ERP, supply chain processes, and compliance strategy are ready for the transition.

Contact the team at Sikich to discuss how we can help you build a life sciences commercialization roadmap that supports launch readiness today and sustainable growth tomorrow.